

PATENT
Customer No. 24,950

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Tabatabaie et al.) Atty Dkt. No.: OKL010-105/00359A
)
SERIAL NO.: Not Yet Assigned)
)
FILED: Herewith)
)
FOR: PREVENTION OF INSULIN-DEPENDENT)
DIABETES OR ALLOGRAFT REJECTION BY)
INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY)

jc997 U.S. PTO
09/05/2587
05/10/01

INFORMATION DISCLOSURE STATEMENT

BOX PATENT APPLICATION
Director - US Patent & Trademark Office
Washington, D. C. 20231

The following sections are being submitted for this Information Disclosure Statement:

1. [X] Preliminary Statements
2. [X] FORM PTO-1449 (Modified)
3. [X] Copies of Listed Information Items Accompanying this Statement
4. [X] Identification of Person(s) Making this Information Disclosure Statement

Express Mail No.: EL555989795US

Date Mailed: May 10, 2001

Section 1. Preliminary Statements

Applicants submit herewith patents, publications or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose.

The filing of this supplemental information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability or that no other material information exists.

Section 2. Form PTO-1449 (Modified)

☒ A completed Form 1449 (Modified) is attached hereto.

☐ No Form 1449 (Modified) is attached.

Section 3. Copies of Listed Information Items Accompanying this Statement

Legible copies of all items listed in Form PTO-1449 (Modified) accompany this information disclosure statement.

Section 4. Identification of Person(s) Making this INFORMATION DISCLOSURE STATEMENT


The person making this statement is the attorney who signs below on the basis of the information:

☒ supplied by the inventor(s)

☐ supplied by an individual associated with the filing and prosecution of this application (37 C.F.R. § 1.56(c)).

☐ in the attorney's file

Respectfully submitted,



Daniel S. Hodgins, Reg. No. 31,026
HEAD, JOHNSON & KACHIGIAN
204 N. Robinson, Ste. 3030
Oklahoma City, OK 73102
(405)236-4000
(405)236-4010 fax

Attorney for Applicants

FORM PTO-1449U.S. DEPARTMENT OF COMMERCE
Patent and Trademark OfficeAttorney's Docket Number
OKL010-105/00359ASerial Number
Not Yet Assigned

(Fill-A-Form 7.92)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use several sheets if necessary)*

Applicants: Tabatabaie et al.

Filing Date Herewith

Group

jcs97 U.S. PTO
19/852587
05/10/01**U. S. PATENT DOCUMENTS**

EXAM INIT.		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

EXAM INIT.		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER MATERIALS*(Including, Author, Title, Date, Relevant Pages, Place of Publication. **)*

EXAM INIT.		
AA	Tabatabaie et al., "spin Trapping Agent Phenyl N-tert-butyl nitron Protects Against the Onset of Drug-Induced Insulin-Dependent Diabetes Mellitus," <u>FFBS Letters</u> , 407:148-152, 1997.	
AB	Tabatabaie et al., "COX-2 Inhibition Prevents Insulin-Dependent Diabetes in Low-Dose Streptozotocin-Treated Mice," <u>Biochem & Biophys. Res. Com.</u> , 273:699-704, 2000.	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant. **Place of Publication refers to name of publication in which the information was published.